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Objective. To evaluate the expression of inflammatory markers in experimental renal failure after fetal programming.Methods.The
offspring aged two and fivemonths were divided into four groups: CC (control dams, control offspring); DC (diabetic dams, control
offspring); CFA (control dams, folic acid offspring, 250mg/Kg); and DFA (diabetic dams, folic acid offspring). Gene expression of
inflammatory markers MCP-1, IL-1, NOS3, TGF-𝛽, TNF-𝛼, and VEGF was evaluated by RT-PCR. Results.MCP-1 was increased in
the CFA and DFA groups at two and five months of age, as well as in DC5 when compared to CC5.There was a higher expression of
IL-1 in the CFA2, DFA2, andDC2 groups.There was a decrease in NOS3 and an increase in TNF-𝛼 in DFA5 in relation to CFA5.The
gene expression of TGF-𝛽 increased in cases that had received folic acid at two and five months, and VEGF decreased in the CFA5
and DFA5 groups. DC5 showed increased VEGF expression in comparison with CC5. Conclusions. Gestational diabetes mellitus
and folic acid both change the expression of inflammatory markers, thus demonstrating that the exposure to harmful agents in
adulthood has a more severe impact in cases which underwent fetal reprogramming.
1. Introduction
The theory of fetal origins of adult disease (FOAD) proposed
by Barker et al. (1986) claims that physiological changes dur-
ing intrauterine development would promote the restriction
of development, as well as ultrastructural and physiological
changes that would predispose to the early development of
cardiovascular and metabolic diseases in adulthood [1–3].
In a model of diabetes in pregnancy, it was demonstrated
that hyperglycemia promotes oxidative stress in the offspring,
hence affecting the balance between oxidant and antioxidant
factors [4], an increase in inflammatory markers, and a
reduction in the number of glomeruli with aging [5].
The Streptozotocin (STZ) may cause mild or severe
diabetesmellitus (DM) in the dam and lead to different effects
in rat offspring [6]. Early blood pressure, deficit in glomerular
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Figure 1: Steps of the experiment.
filtration and in renal plasma flow, and also glomerular
hypertrophy were observed as the offspring aged [5].
Acute renal failure (ARF) is a kidney disorder which may
result from reduced renal perfusion with no cell injury; from
ischemic, toxic, or obstructive injury of the renal tubules;
from tubulointerstitial inflammation and swelling; or from
reduced glomerular filtration rate associated with primary
glomerular diseases [7].
The literature shows the relationship between patholog-
ical changes in adulthood and changes during intrauterine
development, particularly DM. Thus, it is believed that renal
injuries in a fetal programming model are caused by per-
sistent renal inflammatory response due to an injury during
intrauterine life [8].
Some authors demonstrated that gestational diabetes
mellitus may lead to modifications in the placental tran-
scriptome characterized by dominance of genes that regulate
inflammatory responses [9]. Cytokines play a crucial role
in the establishment of inflammatory response and the
systemic inflammation is associated with the development of
endothelial dysfunction and hypertension which may result
in progression of chronic disease [10]. As inflammatory
markers may predict later metabolic [11, 12] and vascular [13]
disease, it is extremely important to measure inflammatory
markers in a fetal programming model.
Therefore, based on the change of the current profile of
patients with ARF and on the association of this entity with
several chronic diseases, the aim of this study was to evaluate
the progression of folic acid-induced ARF in a fetal pro-
grammingmodel through the expression of proinflammatory
markers.
This study aimed to demonstrate the influence of fetal
programming on the development of ARF, as well as the
prognostic evolution of individuals that develop the disease.
2. Methods
This study was submitted to the Ethics Committee on Animal
Use of the Federal University of Triaˆngulo Mineiro and
approved under protocol number 168.
Male and female Wistar rats, with initial weight ranging
from 250 to 330 g, were maintained on a 12 h light-dark cycle
at a constant temperature (25∘C).
2.1. Diabetes-Induction Model. DM was induced by STZ at a
dose of 50mg/Kg after twelve hours of fasting; it was admin-
istered intraperitoneally at a single dose into female rats
weighing 250–330 g. Control animals received the same dose
of vehicle (0.1M Citrate Buffer, pH 4.5). The diabetic state
was confirmed after 48 hours by blood glucosemeasurement.
Only animalswith blood glucose levels above 250mg/dLwere
considered dams (Figure 1).
2.2. Mating. After the induction of diabetes, the estrous cycle
of each rat was determined according to criteria established
in the literature [14]. After a regular cycle, the diabetic
rats were mated at a ratio of one male to one female, and
then a pregnancy test was performed through microscopic
examination of vaginal secretions. The period between the
establishment of the diabetic state andmating lasted 3–7 days.
Females that had spent a period of over seven days and/or two
regular cycles with a male but that did not get pregnant were
considered infertile and discarded in this study (Figure 1).
2.3. Selection of Animals. Approximately 21 days after birth,
all the offspring from each dam were kept in lactation. In this
stage, the pups stayed with the mother in a single cage. From
the 28th day of life, the male rats were separated from their
mothers and placed in collective cages. Male animals at two
and five months of age were studied, comprising a total of 36
young males (Figure 1).
2.4. Development of ARF. The following experiments were
performed when the animals reached the age of two and five
months: the folic acid group received a single intraperitoneal
injection of folic acid (Sigma, St. Louis, MO) at a dose of
250mg/kg in vehicle (0.2mL of 300mM NaHCO3); and the
same volume of vehicle was administered to control animals
(Figures 1 and 2).
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Figure 2: Development of acute renal failure. (a) Normal kidney of offspring who received vehicle; (b) kidney of offspring who received a
single intraperitoneal injection of folic acid, characterized by a yellowish color and increased size; (c) normal kidney of offspring who received
vehicle; (d) kidney of offspring who received a single intraperitoneal injection of folic acid, which present inside the tubules a granular and
yellowish material compatible with folic acid.
2.5. Groups. The animals were divided into four groups, as
follows: (1) CC: control dam and control offspring; (2) CFA:
control dam and folic acid offspring; (3) DC: diabetic dam
and control offspring; and (4) DFA: diabetic dam and folic
acid offspring.
2.6. Euthanasia. Euthanasia was performed 36 hours after
administration of folic acid. The animals were anaesthetized
with a single injection of Ketamine (60mg/kg IM) and
Xylazine (5mg/Kg IM), followed by exsanguination.
2.7. Collection of Sections. Both kidneys of each animal were
collected, weighed, and photographed, and then the renal
capsule was sectioned and removed. The right kidney was
used for histological analysis and the left kidney was used
for molecular biology analysis of gene transcripts. Half of the
left kidney was divided into sections of approximately 50mg,
placed in a 1.5mL polystyrene tube (Eppendorf, Hamburg,
Germany), and immediately frozen in liquid nitrogen and
transferred to a freezer at –80∘C; the other half was fixed in
Karnovsky’s fixative for electron microscopy and in isopen-
tane for further analysis.
2.8. Real-Time Polymerase Chain Reaction (RT-PCR). Gene
expression of monocyte chemoattractant protein-1 (MCP-1),
interleukin-1 (IL-1), NOS3, transforming growth factor-𝛽
(TGF-𝛽), tumor necrosis factor-𝛼 (TNF-𝛼), and vascu-
lar endothelial growth factor (VEGF) was measured by
using TaqMan amplification system (Applied Biosystems,
Branchburg, New Jersey, USA), consisting of a commer-
cial reagent mixture (TaqMan Universal PCR Master Mix,
Applied Biosystems) and of specific custom primers and
probes (Assay-on-Demand 20x, Applied Biosystems). The
reactions using TaqMan system consisted of the following
volumes: Mix TaqMan (5 𝜇L), primer/probe (0.5 𝜇L), cDNA
(1 𝜇L), and sterile water q.s. 10 𝜇L.
2.8.1. Ribonucleic Acid (RNA) Extraction. (1) Less than
100mg of renal tissue was triturated in 1mL of Trizol (Invit-
rogen, Carlsbad, California, USA) using a Polytron PT 1200
CL homogenizer (Kinematica AG, Littau, Switzerland); (2)
the homogenate was incubated for five minutes at room tem-
perature, and 200𝜇L of chloroform p.a. was added (Merck,
Darmstadt, Germany); (3) the homogenate was incubated
for three minutes and centrifuged at 12,000×g at 4∘C for 15
minutes; themixture formed three distinct phases: an organic
phase containing proteins, a white interphase (DNA precip-
itate), and a colorless aqueous phase containing total RNA;
(4) the aqueous phase was transferred to a new tube, to which
500𝜇L isopropanol p.a. (Merck) was added, thus promoting
the precipitation of RNA; (5) the samplewas incubated for ten
minutes and then centrifuged for 10minutes.The precipitated
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RNA formed a substance of gelatinous consistency; the
supernatant was removed and 1mL of 75% p.a. ethanol
solution (Merck) was added to remove the salts from the
Trizol reagent and then homogenized in a vortex mixer; (6)
this solution was centrifuged at 10,500×g in a refrigerated
centrifuge for five minutes; (7) the supernatant was removed,
and the centrifuged solution was dried for ten minutes and
was then rediluted in 50 𝜇L of RNase/DNase-free water; (8)
the RNA was stored in a freezer at –80∘C.
2.8.2. Synthesis of Complementary Deoxyribonucleic Acid
(cDNA). It was synthesized from 2 𝜇g of total RNA pre-
viously treated with DNase (RQ1 RNAse-free DNase)
(Promega, Madison, USA). The following were added to
the treated RNA: 0.2 𝜇g of Oligo(dT)12-18 (GE Healthcare,
Buckinghamshire, UK), 20 ng of BSA (Bovine Serum Albu-
min), 0.1 𝜇mol of dNTPs (Promega), and 400U of M-
MLV reverse transcriptase enzyme (Promega). This mixture
(50mL) was incubated at 37∘C for one hour for reverse
transcription reactions. All samples were run in triplicate
containing a final reaction volume of 10 𝜇L, as follows: 5 𝜇L
of TaqMan Universal PCR Master Mix; 1 𝜇L of cDNA from
each sample; 0,5 𝜇L of primer and probe mix; and, in the
end, ultrapure water q.s. 10 𝜇L. The reaction was performed
in a 7500 Real-Time PCR System thermal cycler (Applied
Biosystems, Singapore). Amplification conditions for the
TaqMan system are standardized and universal for any ampli-
fied PCR product. A comparative analysis of the cycle thresh-
olds (CT) was used in order to determine the gene expres-
sion of MCP-1 (Rn00580555 m1), IL-1 (Rn00580432 m1),
NOS3 (Rn02132634 s1), TGF-𝛽 (Rn00572010 m1), TNF-𝛼
(Rn99999017 m1), and VEGF (Rn01511601 m1). For each
sample, the CT values of the target genes were normalized by
their respective control gene, and the value used to demon-
strate the relative expression of target genes was determined
using the 2−ΔΔCT expression.Thus, relativemRNA levels were
expressed as a difference of “𝑛” times regarding a control sam-
ple; in this study, the same samplewas always used at baseline.
2.9. Statistical Analysis. Normality was assessed using the
Kolmogorov-Smirnov test. For analysis between groups, One
WayANOVA (𝐹) followed by Tukey test was used.The results
were expressed as mean ± standard deviation (𝑋 ± SD).
Values of 𝑝 < 0.05 were considered statistically significant.
3. Results
RT-PCR analysis showed an increase in gene expression for
MCP-1 in the groups that had received folic acid (CFA2 and
DFA2) in comparison with their respective control groups.
The CFA2 group presented MCP-1 significantly higher than
the groups CC2 and DC2 (Figure 3(a)). MCP-1 expression
was similar in animals aged fivemonths that had been treated
with folic acid. This expression was higher in DC5 cases than
inCC5 cases, however, without significant difference between
groups (Figure 4(a)).
There was a higher gene expression for IL-1 in CFA2,
DFA2, and DC2 cases in relation to CC2 cases, however,
without significant difference between groups (Figure 3(b)).
Regarding the animals aged five months, IL-1 expression was
similar among the four groups analyzed (Figure 4(b)).
Gene expression for NOS3 showed no significant dif-
ference in expression between the groups (Figures 3(c) and
4(c)). On the other hand, NOS3 was found to be reduced in
the DFA5 group in comparison with the CFA5 group, despite
the absence of a significant difference (Figure 4(c)).
Nonetheless, a significant increase in gene expression of
TGF-𝛽 was observed between the groups that had received
folic acid (CFA2 and DFA2) when compared to their respec-
tive control groups.TheCFA2 group presented TGF-𝛽 signif-
icantly higher than DC2 group (Figure 3(d)). There was no
significant difference in the expression of TGF-𝛽 between the
groups analyzed at five months. Nevertheless, DC5 cases and
the offspring of control and diabetic dams that had received
folic acid had a higher expression of TGF-𝛽 than CC5 cases
(Figure 4(d)).
The gene expression of TNF-𝛼 was increased in the cases
that had received folic acid (CFA2 and DFA2) compared to
their respective control groups, despite no significant differ-
ence (Figure 3(e)). There was also no significant difference in
TNF-𝛼 expression between the cases analyzed at the age of
five months, even though a higher expression was observed
in the DFA5 group in comparison with the DC5 and CFA5
groups. The DC5 group had higher expression than the
control group (Figure 4(e)).
On the other hand, the gene expression of VEGF was
reduced in the CFA2 and DFA2 groups in relation to their
respective control groups, however, without significant differ-
ence between groups (Figure 3(f)). Furthermore, there was a
significant reduction of VEGF in the groups that had received
folic acid (CFA5 and DFA5).TheDC5 group showed a higher
expression of VEGF than the CC5 group, despite no signifi-
cant difference (Figure 4(f)).
4. Discussion
In this study, folic acid increased the expression of MCP-
1 in the control offspring and in the diabetic offspring only
in two-month group. In different experimental models, folic
acid induces acute renal failure by tubular injury, which
is characterized by apoptosis, proliferation of tubular cells,
inflammatory infiltrate, mild fibrosis, podocyte edema, thin-
ning of pedicel membrane associated with the presence of
vesicles, reduced brush border, and tubular hypertrophy and
obstruction [15] due to the deposition of folic acid crystals.
Therefore,MCP-1 seems to behave as an important biomarker
of renal injury in the evaluated groups.
These changes, associated with hyperglycemia, are
responsible for the increase inMCP-1. An experimental study
on the offspring of diabetic rats correlated the expression of
this proinflammatory cytokine with the chronic activation of
the innate immune system in response to the increased
insulin resistance [16]. Moreover, because of fetal program-
ming, it is believed that the dysfunction of fetal pancreatic
𝛽 cells caused by gestational DM results in permanent meta-
bolic disturbance in postnatal and adult life [16, 17], severe
insulin resistance [5, 16], a reduction in the number of
nephrons and glomeruli, and impaired glomerular filtration
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Figure 3: mRNA gene expression of MCP-1, IL-1, NOS3, TGF-𝛽, TNF-𝛼, and VEGF in the kidney of control offspring and diabetic offspring
with or without folic acid, aged twomonths. (a)The gene expression ofMCP-1 was increased in the CFA2 group; (b and c) the gene expression
of IL-1 and NOS3 showed no significant difference between the study groups; (d) the gene expression of TGF-𝛽 was decreased in the DC2
group; (e and f) the gene expression of TNF-𝛼 and VEGF showed no significant difference between the groups. ∗Significant differences.
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Figure 4: mRNA gene expression of MCP-1, IL-1, NOS3, TGF-𝛽, TNF-𝛼, and VEGF in the kidney of control offspring and diabetic offspring
with or without folic acid, aged five months. (a, b, c, d, and e) The gene expression of MCP-1, IL-1, NOS3, TGF-𝛽, and TNF-𝛼 showed no
significant difference between the study groups; (f) the gene expression of VEGF was decreased in the CFA5 and DFA5 groups. ∗Significant
differences.
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rate [5]. Therefore, these data may explain the higher
expression of MCP-1 in DC5 cases compared to the CC5
cases.
The expression of IL-1 was higher in the two-month
groups, CFA2, DFA2, and DC2. IL-1 is a cytokine involved in
different inflammatory diseases. This cytokine may mediate
acute forms of renal injury, as well as being involved in the
development of chronic kidney disease [18]. Thus, it can be
inferred that the injuries caused by folic acid [15] and by fetal
reprogramming [16] increase the expression of IL-1 in the
two-month-old offspring.
An experimental study showed that intrauterine hyper-
glycemia causes the reduction of pancreatic islets, as well as
a significant increase in glucose intolerance in the diabetic
offspring from the 16th week of development [3]. These
changes are correlated to the action of reactive oxygen species
on pancreatic𝛽 cells, which activate the transmembrane Toll-
like receptors responsible for the synthesis of IL-1 and of other
cytokines in response to the cytotoxic effect [19]. Accordingly,
fetal programming may led to a higher expression of IL-1 in
DC progeny than in CC progeny, as we observed in the two-
month-old offspring.
Comparing the two groups that suffered renal injury by
folic acid, a decreased NOS3 in cases which suffered fetal
reprogramming only in five-month groups was observed.
NOS3 is expressed in the vascular endothelium of the afferent
and efferent arterioles in the kidney [20]. However, in cases
of renal injury, there is a severe uncoupling of NOS3 via
the NADPH oxidase enzyme system and it is responsible for
endothelial ROS production [21].Thus, it can be inferred that
oxidative stress interferes with its synthesis and activity. DM
compromises the activity of phosphatidylinositol 3-kinase
and the activation of protein kinase B, which is responsible for
phosphorylation and activation of NOS3. Interference in this
pathway inhibits the oxidation of L-arginine to NO as well
as the stability of NOS3 mRNA [20]. The reduced expression
of DFA5 compared to CFA5 also indicates a greater impact
of folic acid injury on the diabetic progeny, and it shows
that fetal reprogramming interferes with the development of
changes.
Gene expression of TGF-𝛽 was higher in the CFA2 and
DFA2 groups. This data is in accordance with the literature,
since folic acid is associated with mitochondrial dysfunction
in renal failure. An experimental study showed that TGF-𝛽
levels increase up to four times six days after induction of
renal injury [22].
Therefore, the higher mRNA synthesis of this cytokine in
podocytes contributes to mesangial matrix expansion, GBM
thickening, and proliferation, hypertrophy, and apoptosis
[23–25] of podocytes and proximal tubular cells. Thus,
these findings seem to explain the higher expression of this
cytokine in the CFA2 and DFA2 groups.
TGF-𝛽 gene expression also showed the influence of age
on the analyzed progeny, since the DC5 group was older. The
hyperglycemic state promotes glycation of proteins, diacyl-
glycerol synthesis, and activation of protein kinase C that
favor its expression [23, 26]. Hence, these results confirm the
interference of fetal programming in the analyzed progeny.
Moreover, the higher expression in the DC5 group compared
to CC5 group indicates a more evident late renal failure.
TNF-𝛼 expressionwas higher in both theCFA2 andDFA2
groups and also in the DFA5 group when compared to the
DC5 and CFA5 groups. Studies have showed that the levels of
this inflammatory cytokine are increased by 25 times in the
renal tissue of rats 48 hours after administration of folic acid,
which was associated not only with a higher prevalence of
epithelial apoptosis and necrosis [27, 28], but also with glom-
erular hypercellularity and mesangial expansion [29].
The literature shows that the development of maternal
insulin resistance appears to be responsible for the increase
in TNF-𝛼 levels from the first stage of prenatal development
to the 28th week [30]. The increased expression of TNF-𝛼 in
DFA5 cases in relation to CFA5 cases also indicates a greater
impact of folic acid injury in diabetic offspring, hence indicat-
ing that fetal reprogramming interferes with the progressive
changes that appear in late adulthood.
VEGF gene expression was lower in both the CFA2 and
DFA2 groups, as well as in the CFA5 and DFA5 groups.
Folic acid appears to interfere with VEGF expression, since
there is a reduction in the expression of this growth factor 14
days after administration. The progression of nephrotoxicity
is believed to be responsible for both attenuating receptor
expression and for interfering with VEGF synthesis, which
occurs via intracellular signaling pathways [31].
On the other hand, gene expression increased in the
DC5 group. In DM, renal hypoxia promotes VEGF synthesis
via the accumulation of hypoxia-inducible factor. Similarly,
hyperglycemia caused by activation of extracellular signal-
regulated kinase in podocytes and by advanced glycation end
products (AGEs) [32] is responsible for the expression of this
factor.
DM causes early ultrastructural changes, such as mesan-
gial and endothelial cell proliferation, GBM thickening, and
erasure of pedicels [33], as well as late ultrastructural changes,
such as apoptosis of renal cells through increased expression
of proapoptotic proteins Bim and Bax, and consequent
increase in the activation of caspase-3 [34]. Therefore, the
progression of this disease may have promoted gene expres-
sion of VEGF in diabetic offspring aged two and five months
in this study.
Studies on fetal reprogramming in humans are scarce due
to the difficulty of selecting adults who have suffered some
type of aggression during their fetal development, whichmay
be confirmed through maternal medical records and, there-
fore, be able to assess the late consequences of these aggres-
sions. In the literature are found some longitudinal [35] and
cohort studies [36] on human fetal reprogramming. There
are also some studies with Holocaust survivors born during
WorldWar II proving the late effects of nutritional deficiency
during fetal development on adults and their offspring due
to maternal malnutrition and hunger. The results of these
studies indicate that these individuals were more likely to
present dyslipidemia, hypertension, vascular disease, dia-
betes mellitus, metabolic syndrome, and premature osteope-
nia/osteoporosis [37–39].
However, acquiring human samples of biopsies and asso-
ciating the data with intrauterine aggression history may be
8 Journal of Immunology Research
very difficult or even infeasible. Because of this, experimental
studies on fetal reprogramming are extremely important to
simulate something that may occur in humans and, thus, be
able to understand the molecular mechanisms involved in
this process. This experimental study suggests that metabolic
dysfunctions triggered by DM during pregnancy and by folic
acid during intrauterine life culminate in fetal programming
of descendant offspring in postnatal life. The decrease in
NOS3 and increase in TNF-𝛼 indicate a greater impact of folic
acid injury in diabetic offspring, and they also show that fetal
reprogramming interferes with the development of changes
that appear in late adulthood.
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